Loading viewer...
investor_presentation
Format: PDF investor_presentation
Tyra Biosciences is developing next-generation oncology drugs designed to target acquired drug resistance with improved tolerability. The company's pipeline includes FGFR-selective inhibitors addressing FGFR3, FGFR2, RET, FGFR4, and achondroplasia indications.
presentation
investor_presentation
22 Pages
Simon Property Group
investor_presentation
EOG Resources